M6a Methyltransferase METTL3 Promotes Non-Small-cell Lung Carcinoma Progression by Inhibiting the RIG-I-MAVS Innate Immune Pathway

Tinghui Huang,Xudong Ao,Jie Liu,Chuancheng Sun,Yunfei Dong,Xuechen Yin,Yan Zhang,Xinping Wang,Wenying Li,Jiujiu Cao,Feiyan Pan,Zhigang Hu,Zhigang Guo,Lingfeng He
DOI: https://doi.org/10.1016/j.tranon.2024.102230
IF: 4.803
2024-01-01
Translational Oncology
Abstract:Our experimental study showed that METTL3 was highly expressed in NSCLC cells and promoted the growth of tumor cells. METTL3 takes N6-methyladenosine (m6A) as the main means of mRNA modification to control the expression and function of RIG-I-MAVS signalling pathway. RIG-I-MAVS constitute the first line frontier in the innate immune defense of human cells. Activation of RIG-I-MAVS signaling can inhibit tumor cell growth and activate the immune microenvironment. Our experimental data reveal that lung cancer cells utilize METTL3-mediated methylation modifications to inhibit the activation of RIG-I-MAVS signaling pathway and immune responses. Our work provides new ideas for biotherapy and immunotherapy.
What problem does this paper attempt to address?